Literature DB >> 22922072

Hyperfibrinolysis is common in out-of-hospital cardiac arrest: results from a prospective observational thromboelastometry study.

H Schöchl1, J Cadamuro, S Seidl, A Franz, C Solomon, C J Schlimp, B Ziegler.   

Abstract

BACKGROUND: Cardiocirculatory arrest (CCA) activates procoagulant pathways. It has also been reported to inhibit fibrinolysis, resulting in fibrin deposition and further impairment of blood flow. Until now, no studies have used whole-blood viscoelastic tests to characterize coagulation and the impact of fibrinolysis in out-of-hospital cardiac arrest (OHCA).
METHODS: Patient with established OHCA who underwent cardiopulmonary resuscitation (CPR) were enrolled. Blood samples were obtained immediately after placement of an intravenous line at the scene, for full blood cell count, standard coagulation tests and rotational thromboelastometric (ROTEM(®)) analyses. Patients with return of spontaneous circulation (ROSC) were compared to non-ROSC patients.
RESULTS: Fifty-three patients (median age 67 years, interquartile range: 56-73 years) were included in the study. ROSC was established in 25 patients. Prothrombin time index (PTI) was significantly lower and activated partial thromboplastin time (aPTT) was significantly prolonged in non-ROSC patients compared to ROSC patients. Clotting time (CT) in the extrinsically activated ROTEM test (EXTEM) was significantly longer in non-ROSC versus ROSC patients. For the remaining EXTEM parameters, there were no significant differences between ROSC and non-ROSC patients. Hyperfibrinolysis (maximum lysis>15% according to ROTEM test results) was observed in 19 patients (35.8%). There was no difference between ROSC and non-ROSC patients in the incidence of hyperfibrinolysis.
CONCLUSIONS: PTI, aPTT and EXTEM CT revealed significant differences between ROSC and non-ROSC patients. Hyperfibrinolysis according to ROTEM test results was much more common than previously assumed. Routine use of fibrinolytic therapy in all patients with prolonged CPR cannot therefore be recommended.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22922072     DOI: 10.1016/j.resuscitation.2012.08.318

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  26 in total

1.  [Uncritical use of tranexamic acid in trauma patients : Do no further harm!]

Authors:  M Maegele
Journal:  Unfallchirurg       Date:  2016-11       Impact factor: 1.000

2.  Redefining postinjury fibrinolysis phenotypes using two viscoelastic assays.

Authors:  Gregory R Stettler; Ernest E Moore; Hunter B Moore; Geoffrey R Nunns; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2019-04       Impact factor: 3.313

3.  Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient.

Authors:  Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Angela Sauaia; Anirban Banerjee; Christopher C Silliman
Journal:  Transfusion       Date:  2016-04       Impact factor: 3.157

4.  Fibrinolysis shutdown phenotype masks changes in rodent coagulation in tissue injury versus hemorrhagic shock.

Authors:  Hunter B Moore; Ernest E Moore; Peter J Lawson; Eduardo Gonzalez; Miguel Fragoso; Alex P Morton; Fabia Gamboni; Michael P Chapman; Angela Sauaia; Anirban Banerjee; Christopher C Silliman
Journal:  Surgery       Date:  2015-06-05       Impact factor: 3.982

5.  Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients.

Authors:  Hunter B Moore; Ernest E Moore; Ioannis N Liras; Eduardo Gonzalez; John A Harvin; John B Holcomb; Angela Sauaia; Bryan A Cotton
Journal:  J Am Coll Surg       Date:  2016-01-22       Impact factor: 6.113

6.  Viscoelastic Tissue Plasminogen Activator Challenge Predicts Massive Transfusion in 15 Minutes.

Authors:  Hunter B Moore; Ernest E Moore; Michael P Chapman; Benjamin R Huebner; Peter M Einersen; Solimon Oushy; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  J Am Coll Surg       Date:  2017-05-15       Impact factor: 6.113

7.  Shock-induced systemic hyperfibrinolysis is attenuated by plasma-first resuscitation.

Authors:  Hunter B Moore; Ernest E Moore; Alexander P Morton; Eduardo Gonzalez; Miguel Fragoso; Michael P Chapman; Monika Dzieciatkowska; Kirk C Hansen; Anirban Banerjee; Angela Sauaia; Christopher C Silliman
Journal:  J Trauma Acute Care Surg       Date:  2015-12       Impact factor: 3.313

8.  Tissue injury suppresses fibrinolysis after hemorrhagic shock in nonhuman primates (rhesus macaque).

Authors:  Antoni R Macko; Hunter B Moore; Andrew P Cap; M Adam Meledeo; Ernest E Moore; Forest R Sheppard
Journal:  J Trauma Acute Care Surg       Date:  2017-04       Impact factor: 3.313

9.  Viscoelastic measurements of platelet function, not fibrinogen function, predicts sensitivity to tissue-type plasminogen activator in trauma patients.

Authors:  H B Moore; E E Moore; M P Chapman; E Gonzalez; A L Slaughter; A P Morton; A D'Alessandro; K C Hansen; A Sauaia; A Banerjee; C C Silliman
Journal:  J Thromb Haemost       Date:  2015-09-22       Impact factor: 5.824

10.  Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy.

Authors:  Hunter B Moore; Ernest E Moore; Eduardo Gonzalez; Michael P Chapman; Theresa L Chin; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2014-12       Impact factor: 3.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.